SAN DIEGO and ST OUEN L'AUMONE, France, May 30, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it, along with its wholly owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has entered into technology licensing and marketing agreements with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. These agreements will expand access to Sequenom CMM's MaterniT21™ PLUS laboratory-developed test and the technology used in the test to healthcare providers and their patients via Laboratoire Cerba's network in France, Belgium, Luxembourg and portions of the Middle East and Africa.
"This new relationship with Laboratoire Cerba, one of the leading diagnostics service providers in Europe, will enable us to leverage Laboratoire Cerba's strong network of facilities to provide healthcare providers and their patients with access to our innovative noninvasive prenatal testing (NIPT) technology," said William Welch, President and COO, Sequenom, Inc. "We look forward to collaborating with Cerba to continue to build upon the momentum we've seen with the adoption of our testing services worldwide."
Under the terms of the license agreement, Sequenom will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France. Laboratoire Cerba will also have rights to market its noninvasive testing service in multiple countries, including France, Luxembourg, Belgium, Lebanon, Morocco, Algeria, Tunisia, Libya, Senegal, Ivory Coast, Burkina Faso and Cameroun. Effective immediately, the contract term for the technology license is active through 2018.
"Combining Sequenom CMM's prenatal testing technology with our laboratory testing expertise and network is great news for expectant families in Europe, as we will be able to provide them important information about their pregnancies in an accurate, safe and efficient method," said Sylvie CADO, COO, Laboratoire Cerba. "We believe our markets are anxious for access to NIPT technology, and we are enthusiastic to develop this innovative test in France. This collaboration gives us the opportunity to increase our portfolio in the field of noninvasive prenatal diagnosis. We look forward to a successful and productive relationship with Sequenom and Sequenom CMM."The MaterniT21 PLUS LDT analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks' gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom CMM as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com. About SequenomSequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site. About Sequenom Center for Molecular MedicineSequenom Center for Molecular Medicine (Sequenom CMM ®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory currently with two locations dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by health care professionals in managing patient care. Testing services are available only upon request by physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.sequenomcmm.com for more information on laboratory testing services. SEQUENOM ®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners. About Laboratoire CerbaLaboratoire Cerba is a leading European specialized laboratory based in France and ISO 15189 accredited. Since its inception in 1967, it offers private laboratories and public hospitals in more than 35 countries a broad range of specialty testing services, such as molecular biology testing, oncology testing, allergy testing, hormonology testing, infectious disease testing and diagnostic genetic testing and has developed a broadly recognized expertise in innovation for new tests. It is the founding member of the Cerba European Lab Group, a leading European clinical pathology laboratory, providing routine and specialized clinical laboratory testing services primarily in France, Belgium and Luxembourg, and supporting pharmaceutical and biotechnology companies worldwide in the clinical trial phase of their drug development processes. Through its Routine Lab and Specialized Testing operations, the Group offers a range of over 2000 routine and specialty clinical tests used by doctors and medical institutions to diagnose, monitor and treat diseases. The Central Lab testing operations, which operated through the BARC subsidiaries, provide safety and efficacy testing services to pharmaceutical companies and contact research organizations worldwide in connection with drug development processes.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV